Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty?
Shallis RM, Zeidan AM. Lenalidomide in non-deletion 5q lower-risk myelodysplastic syndromes: a glass quarter full or three quarters empty? Leukemia & Lymphoma 2018, 59: 2015-2017. PMID: 29411698, DOI: 10.1080/10428194.2018.1430797.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAbnormalities, MultipleChromosome DeletionChromosomes, Human, Pair 2HumansLenalidomideMyelodysplastic Syndromes